Streetbeat News

Regulatory

NIO

NIO Inc. shares traded higher after China announced measures to optimize its business environment. The company saw more than double its average daily options volume, with calls outpacing puts by more than three to one. Traders expect NIO's stock to move higher through the end of the week. NIO shares jumped 10.9% to close at $11.73 on Monday, and added 3.9% in Tuesday's premarket trading session.

Portfolio Pulse from Lisa Levin

July 25, 2023 | 1:19 pm

MBOT

Microbot Medical is engaging with a leading notified body to secure a CE Mark for sales in Europe, according to an SEC filing. This move could potentially open up a new market for the company's products.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 1:17 pm

MBIO

MindBio Therapeutics Corp. has begun recruiting participants for a phase 2 clinical trial using microdoses of LSD and psychotherapy to treat emotional distress in advanced stage cancer patients. The trial will involve 40 participants over a 6-week period. The company aims to address the high prevalence of depression, anxiety, and reduced quality of life in advanced-stage cancer patients.

Portfolio Pulse from Vuk Zdinjak

July 25, 2023 | 1:12 pm

GCTK

Glucotrack, Inc. (NASDAQ:GCTK) has announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The study confirmed that the CGM sensor design could reliably report glucose measurements for two years post-implant. The company is now preparing for long-term animal studies.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 1:04 pm

BLPH

Bellerophon Therapeutics has received a delisting notice, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 1:01 pm

THRD

Third Harmonic Bio, Inc. (NASDAQ:THRD) has announced its next-generation product candidate, THB335, a potent oral KIT inhibitor for inflammatory diseases. The company plans to file a U.S. IND and initiate clinical trials of THB335 in the first half of 2024. The previous product, THB001, was discontinued due to observed liver transaminitis in two of five patients. However, THB335 is believed to address this risk with its differentiated metabolic profile.

Portfolio Pulse from Happy Mohamed

July 25, 2023 | 12:42 pm

ONDS

Ondas Holdings Inc. (NASDAQ:ONDS) has announced that its subsidiary, Airobotics, is partnering with Aero A2Z to expand into the Indian market. The partnership will market and support the Optimus Unmanned Aerial Systems (UAS) and Iron Drone Counter-Unmanned Aerial Systems (C-UAS) solutions for Smart Cities, Government, and Industrial entities in India. The companies will be jointly participating in the International Drone Expo in New Delhi on July 26 - 27.

Portfolio Pulse from Happy Mohamed

July 25, 2023 | 12:39 pm

MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received authorization from Health Canada for its medication LIVMARLI® (maralixibat oral solution) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). This approval is supported by over six years of LIVMARLI data showing improvements in pruritus and serum bile acids. LIVMARLI is also approved in the United States and Europe for the same indication. Mirum has submitted a supplemental new drug application to the FDA and EMA for approval of LIVMARLI in cholestatic pruritus associated with progressive familial intrahepatic cholestasis (PFIC).

Portfolio Pulse from Happy Mohamed

July 25, 2023 | 12:36 pm

ATXI

Avenue Therapeutics has announced an agreement with the FDA on the study design and analysis approach of the Phase 3 safety study for IV Tramadol.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 12:34 pm

LLY

The European Commission has approved Jardiance (Empagliflozin), a drug developed in partnership by Boehringer Ingelheim and Eli Lilly, for use in adults with chronic kidney disease.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 12:18 pm